A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937

For most doses in the single‐dose administration study and all doses in the repeat‐dose administration study, the HIV‐1 maturation inhibitor GSK3739937 remained detectable in the plasma of healthy participants for at least 2 weeks after the last dose. Due to this generally long half‐life, repeated daily oral dosing resulted in dose‐proportional accumulation of GSK3739937; however, more limited accumulation was observed after once‐weekly dosing. Overall, the data support further development of GSK3739937 as an oral therapy administered once per week.